2-piperidone has been researched along with Recrudescence in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouabdallah, R; Buchholz, TJ; Carpio, C; Carrancio, S; Cordoba, R; Couto, S; Damian, S; Gandhi, AK; Gharibo, M; Hagner, PR; Hege, K; Lopez-Martin, JA; Martin, A; Panizo, C; Pinto, A; Pourdehnad, M; Rasco, D; Ribrag, V; Risueño, A; Salar, A; Salles, G; Sancho, JM; Santoro, A; Schmitz, F; Trotter, MWB; Van den Neste, E; Verhoef, G; Wang, M; Wang, X; Wei, X; Weng, A; Ysebaert, L | 1 |
| Bijou, F; Bouabdallah, R; Chen, T; Chiappella, A; Doorduijn, JK; Hagner, PR; Hege, K; Kersten, MJ; Klein, C; Mendez, C; Michot, JM; Mosulen, S; Nikolova, Z; Pourdehnad, M; Ribrag, V; Salles, G; Sarmiento, R; Uttamsingh, S; Vitolo, U; Zinzani, PL | 1 |
| Anderson, AA; Becker, PS; Erba, HP; Flesher, DL; Grunwald, MR; Henary, HA; Rasmussen, E; Shami, PJ; Wang, ES; Zhu, M | 1 |
| Aravindan, N; Aravindan, S; Awasthi, V; Herman, TS; Natarajan, M | 1 |
2 trial(s) available for 2-piperidone and Recrudescence
| Article | Year |
|---|---|
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Half-Life; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Piperidones; Quinazolinones; Recurrence; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2020 |
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Piperidones; Proto-Oncogene Proteins c-mdm2; Pyridones; Pyrimidinones; Recurrence; Treatment Outcome | 2019 |
2 other study(ies) available for 2-piperidone and Recrudescence
| Article | Year |
|---|---|
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Drug Resistance, Neoplasm; Female; Humans; Immunophenotyping; Lymphoma, Large B-Cell, Diffuse; Macrophages; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Piperidones; Prognosis; Quinazolinones; Recurrence; Retreatment; T-Lymphocytes; Treatment Outcome | 2020 |
Novel synthetic monoketone transmute radiation-triggered NFκB-dependent TNFα cross-signaling feedback maintained NFκB and favors neuroblastoma regression.
Topics: Benzylidene Compounds; Cell Line, Tumor; Cell Survival; Clone Cells; Extracellular Space; Feedback, Physiological; Humans; Neuroblastoma; NF-kappa B; Piperidones; Recurrence; Signal Transduction; Telomerase; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2013 |